Scientists track immune clues to improve cancer treatment

NCT ID NCT03514368

Recruiting now Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Feb 19, 2026 · Last updated May 15, 2026 · Updated 12 times

Summary

This study aims to find biological markers in blood and tumor samples that can predict how well immunotherapy works and what side effects may occur. It will enroll 770 adults with advanced solid cancers like lung, head and neck, melanoma, or bladder cancer who are receiving immune checkpoint inhibitors. Participants provide samples at several time points and are followed until their cancer progresses. The goal is to improve future treatment decisions, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chu Rangueil
RECRUITING

Toulouse, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hopital Larrey
RECRUITING

Toulouse, 31059, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut Universitaire Du Cancer de Toulouse - Oncopole
RECRUITING

Toulouse, 31059, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID CANCERS